FibroBiologics Announces Release of CYWC628 Drug Product for Phase 1/2 Diabetic Foot Ulcer Clinical Trial
FibroBiologics has released the first cGMP-compliant batch of its investigational drug CYWC628 designed for treating diabetic foot ulcers (DFUs). This release enables the commencement of a Phase 1/2 clinical trial to evaluate the safety, tolerability, and preliminary efficacy of CYWC628. The milestone represents progress in the company’s developmen…